US 12351560
Next generation FKBP52 targeting drugs for the treatment of prostate and breast cancer
granted A61KA61K31/4196A61K31/502
Quick answer
US patent 12351560 (Next generation FKBP52 targeting drugs for the treatment of prostate and breast cancer) held by The Board of Regents of the University of Texas System expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The Board of Regents of the University of Texas System
- Grant date
- Tue Jul 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 10
- CPC classes
- A61K, A61K31/4196, A61K31/502, A61K45/06